Pulmonology

A re-prioritization of disease monitoring and screening could help physicians better understand how one of the greatest killers in the US could be combated.

Results of the VESUVIUS trial are adding fuel to the fire in the debate over the impact of electronic cigarettes in former tobacco users.

An assessment of metoprolol in older patients with COPD had to be discontinued after treated patients reported a greater rate of hospitalization due to exacerbations.

The Senate voted 72-18 to support the successor to Scott Gottlieb, MD, following a November hearing which raised questions to his stance on proposed tobacco and e-cigarette policies.

A new study presented at ASH 2019 is providing further evidence for the use of weight-adjusted rivaroxaban in children with venous thromboembolism.

A new analysis has found the switch to the “increased-risk” donor classification by the US Public Health Service has had minimal impact on outcomes of lung transplants.

Artificial intelligence could provide physicians with easier, quicker measures of coronary artery calcium.

In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.

A new cohort analysis shows hospitalized smokers are not at complication risk due to the perioperative therapy.

An international, 5000-patient cohort shows a majority of patients are white, female, and non-smokers.

Are current methods and biomarkers viable, or are there better options to uncover?

In months, the US may have its first marketed peanut immunotherapies. How will pediatric patient management change?

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

How to weigh the 5 agents from the drug class, which have each shown differing benefit in younger patients.

For what other indications, and in what regimens, are investigators assessing the drug class?

The IL-5 inhibitor has shown significant benefits for HES in a phase 3 pivotal trial, and is now being considered for regulatory submission.

Certain diet-based comorbid conditions are more prevalent in food-allergic patients.

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.

How the greatest use of the drug class may just come in the most severe cases.

The rate of pediatric and adolescent patients adhering to 30-day corticosteroid refill schedules increased by nearly 50 percentage points.

How can physicians train parents to trust immunotherapy—an allergen exposure they were previously told to avoid?

A growing patient population and burdens of physician shortage require specialists and primary care collaborate more and more.

Assessing a food allergy patient's overall diet during immunotherapy trials could unlock understanding how the microbiome affects the allergic reaction.

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.